An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.

Claims

56 · 4 independent · depth 3

56 granted claims

›1.independentAn isolated anti-glypican 3 antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in S…+3

›2.independentAn isolated anti-glypican 3 antibody selected from the group consisting of the antibody of any one of (1)-(7):n(1) an antibody comprising a heavy chai…+15

›6.↳ 2A pharmaceutical composition comprising the antibody as claimed in claim 2.d2

›13.↳ 2The antibody of claim 2, wherein the antibody is:n(1) an antibody comprising a heavy chain variable region comprising the amino acid sequence set fort…d2+1

›15.↳ 2The antibody of claim 2, wherein the antibody is:n(2) an antibody comprising a heavy chain variable region comprising the amino acid sequence set fort…d2+1

›17.↳ 2The antibody of claim 2, wherein the antibody is:n(3) an antibody comprising a heavy chain variable region comprising the amino acid sequence set fort…d2+1

›19.↳ 2The antibody of claim 2, wherein the antibody is:n(4) an antibody comprising a heavy chain variable region comprising the amino acid sequence set fort…d2+1

›21.↳ 2The antibody of claim 2, wherein the antibody is:n(5) an antibody comprising a heavy chain variable region comprising the amino acid sequence set fort…d2+1

›23.↳ 2The antibody of claim 2, wherein the antibody is:n(6) an antibody comprising a heavy chain variable region comprising the amino acid sequence set fort…d2+1

›25.↳ 2The antibody of claim 2, wherein the antibody is:n(7) an antibody comprising a heavy chain variable region comprising the amino acid sequence set fort…d2+1

›4.independentAn isolated monoclonal antibody capable of binding to an epitope of glypican 3 to which a second antibody is capable of binding, wherein said second a…+3

›7.independentAn isolated anti-glypican 3 antibody comprising any one of (1)-(15) below:n(1) a heavy chain variable region having CDRs 1, 2 and 3 comprising the ami…+31

An isolated anti-glypican 3 antibody comprising any one of (1)-(15) below:n(1) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 174, 144 and 158, respectively;(2) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 175, 144 and 158, respectively;(3) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 176, 144 and 158, respectively;(4) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 177, 144 and 158, respectively;(5) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 178, 144 and 158, respectively;(6) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 179, 144 and 158, respectively;(7) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 180, 144 and 158, respectively;(8) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 181, 144 and 158, respectively;(9) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 182, 144 and 158, respectively;(10) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 183, 144 and 158, respectively;(11) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 184, 144 and 158, respectively;(12) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124, and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 185, 144, and 158, respectively;(13) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124, and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 186, 144 and 158, respectively;(14) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 187, 144 and 158, respectively; and(15) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 188, 144 and 158, respectively.

›10.↳ 7A pharmaceutical composition comprising the antibody as claimed in claim 7.d2

›27.↳ 7The antibody of claim 7, wherein the antibody comprises:n(1) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence s…d2+1

›29.↳ 7The antibody of claim 7, wherein the antibody comprises:n(2) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence s…d2+1

›31.↳ 7The antibody of claim 7, wherein the antibody comprises:n(3) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence s…d2+1

›33.↳ 7The antibody of claim 7, wherein the antibody comprises:n(4) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence s…d2+1

›35.↳ 7The antibody of claim 7, wherein the antibody comprises:n(5) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence s…d2+1

›37.↳ 7The antibody of claim 7, wherein the antibody comprises:n(6) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence s…d2+1

›39.↳ 7The antibody of claim 7, wherein the antibody comprises:n(7) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence s…d2+1

›41.↳ 7The antibody of claim 7, wherein the antibody comprises:n(8) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence s…d2+1

›43.↳ 7The antibody of claim 7, wherein the antibody comprises:n(9) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence s…d2+1

›45.↳ 7The antibody of claim 7, wherein the antibody comprises:n(10) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence …d2+1

›47.↳ 7The antibody of claim 7, wherein the antibody comprises:n(11) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence …d2+1

›49.↳ 7The antibody of claim 7, wherein the antibody comprises:n(12) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence …d2+1

›51.↳ 7The antibody of claim 7, wherein the antibody comprises:n(13) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence …d2+1

›53.↳ 7The antibody of claim 7, wherein the antibody comprises:n(14) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence …d2+1

›55.↳ 7The antibody of claim 7, wherein the antibody comprises:n(15) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence …d2+1

Classifications

7 codes

IPC · International Patent Classification

Section C — Chemistry; metallurgy

C07K16/28
C12P21/06
C07H21/04
C12N5/06

USPC · US Patent Classification

424/133.1536/23.53530/388.22

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

5.1 y

1,866 days filing → grant

Office actions

after a restriction

Responses

1 RCE

Interviews

examiner interview summaries

Examiner

Lynn Bristol

art unit 1643 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 157 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20070190599 A1	16 Aug 2007

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.